Cystic Fibrosis (CF) is one of the most common life-threatening genetic disorders worldwide. For couples who are carriers of the CFTR gene mutation, the dream of starting a family often comes with the fear of passing this condition to their children. However, advancements in reproductive technology, specifically In Vitro Fertilization (IVF) combined with Preimplantation Genetic Testing for Monogenic Disorders (PGT-M), have made it possible to significantly reduce this risk.
At our clinic in Istanbul, Turkey, we specialize in helping international patients navigate the complexities of genetic screening and fertility treatments, ensuring a path toward a healthy pregnancy with expert medical guidance and state-of-the-art laboratory technology.
Understanding Cystic Fibrosis and Inheritance
Cystic Fibrosis is an autosomal recessive genetic disorder. This means that for a child to be born with the condition, they must inherit two copies of the defective CFTR gene—one from each parent. If both parents are "carriers" (meaning they have one mutated gene but do not show symptoms), there is a:
- 25% chance the child will have Cystic Fibrosis.
- 50% chance the child will be an asymptomatic carrier.
- 25% chance the child will be completely unaffected.
Many couples only discover they are carriers through carrier screening or after the birth of a child with CF. For those who know their risk, IVF with PGT-M offers an essential preventive strategy.
The Role of PGT-M in Preventing Cystic Fibrosis
PGT-M (formerly known as PGD) is a specialized laboratory procedure used during an IVF cycle. Unlike standard IVF, where embryos are selected based on their appearance, PGT-M analyzes the genetic makeup of the embryo specifically to look for the CFTR mutation.
How the PGT-M Process Works
- Ovarian Stimulation and Egg Retrieval: The mother undergoes a standard IVF cycle to produce multiple eggs, which are then fertilized in the lab.
- Embryo Culture: The resulting embryos are grown to the blastocyst stage (usually day 5 or 6).
- Embryo Biopsy: A few cells are carefully removed from the trophectoderm (the part that becomes the placenta). This does not harm the inner cell mass that becomes the baby.
- Genetic Analysis: The DNA from these cells is tested for the specific Cystic Fibrosis mutation identified in the parents.
- Embryo Transfer: Only embryos that are found to be unaffected by Cystic Fibrosis (either non-carriers or healthy carriers) are selected for transfer to the uterus.
Why Choose IVF for Cystic Fibrosis Prevention?
The primary benefit of IVF with PGT-M is the peace of mind it offers. By testing embryos before implantation, couples can avoid the difficult decision of whether to continue a pregnancy if a prenatal test (like amniocentesis) reveals the fetus has CF. It is currently the most proactive method available for preventing the transmission of monogenic disorders.
Furthermore, many male patients with Cystic Fibrosis suffer from Congenital Bilateral Absence of the Vas Deferens (CBAVD), which causes infertility despite normal sperm production. In these cases, surgical sperm retrieval (like TESE or micro-TESE) can be performed in Istanbul to collect sperm directly from the testes for use in IVF.
IVF and Genetic Testing in Turkey
Istanbul has emerged as a global hub for reproductive medicine. Patients choose Turkey for Cystic Fibrosis-related IVF treatments for several reasons:
- Advanced Laboratory Infrastructure: Turkish clinics utilize the latest NGS (Next-Generation Sequencing) technology for highly accurate genetic results.
- Experienced Geneticists: PGT-M requires custom-built "probes" for each couple; our specialists are experts in identifying rare CFTR mutations.
- Affordability: The cost of IVF and PGT-M in Turkey is significantly lower than in the UK, USA, or much of Europe, without compromising on medical quality or success rates.
- Comprehensive Care: From the initial carrier screening to the final embryo transfer, we provide a seamless experience for international patients.
Success Rates and Considerations
It is important to understand that the success of IVF with PGT-M depends on various individual factors, including the mother’s age, ovarian reserve, and the number of healthy embryos available after genetic testing. While PGT-M is highly accurate (typically over 98%), it does not guarantee a pregnancy or a live birth. Our consultants provide a personalized assessment to manage expectations and optimize the chances of a healthy outcome.
Frequently Asked Questions
Can PGT-M detect ALL mutations of Cystic Fibrosis?
Yes, as long as the specific mutation in the parents has been identified through carrier screening. PGT-M is a bespoke test designed to look for the exact genetic marker problematic for a specific couple, allowing for high precision.
Is the embryo biopsy safe?
Modern biopsy techniques are performed by highly skilled embryologists at the blastocyst stage. Research indicates that when performed correctly, the biopsy does not increase the risk of birth defects or significantly impact the embryo's ability to implant.
Do I need IVF even if I am fertile?
Yes. Even if a couple has no trouble conceiving naturally, IVF is necessary to perform PGT-M. The IVF process is the only way to access the embryos in a laboratory setting to conduct genetic testing before a pregnancy is established.
If you or your partner are carriers of Cystic Fibrosis, taking the next step toward a healthy family starts with a consultation. Contact our team in Istanbul today to learn more about how we can help you navigate your fertility journey.